<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006531</article-id><article-id pub-id-type="pmc">PMC11859453</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020164</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00164</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development, Characterization, and Evaluation of Chi-Tn mAb-Functionalized DOTAP-PLGA Hybrid Nanoparticles Loaded with Docetaxel for Lung Cancer Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8226-1364</contrib-id><name><surname>Castro</surname><given-names>Anal&#x000ed;a</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00164" ref-type="aff">1</xref><xref rid="fn1-pharmaceutics-17-00164" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8342-804X</contrib-id><name><surname>Pittini</surname><given-names>&#x000c1;lvaro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceutics-17-00164" ref-type="aff">2</xref><xref rid="af3-pharmaceutics-17-00164" ref-type="aff">3</xref><xref rid="fn1-pharmaceutics-17-00164" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6372-2540</contrib-id><name><surname>Berois</surname><given-names>Nora</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceutics-17-00164" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1650-7677</contrib-id><name><surname>Faccio</surname><given-names>Ricardo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00164" ref-type="aff">1</xref><xref rid="af4-pharmaceutics-17-00164" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1195-3144</contrib-id><name><surname>Miranda</surname><given-names>Pablo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-pharmaceutics-17-00164" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7795-2638</contrib-id><name><surname>Mombr&#x000fa;</surname><given-names>&#x000c1;lvaro W.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00164" ref-type="aff">1</xref><xref rid="af4-pharmaceutics-17-00164" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2283-7066</contrib-id><name><surname>Osinaga</surname><given-names>Eduardo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceutics-17-00164" ref-type="aff">2</xref><xref rid="af3-pharmaceutics-17-00164" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0986-4580</contrib-id><name><surname>Pardo</surname><given-names>Helena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00164" ref-type="aff">1</xref><xref rid="af4-pharmaceutics-17-00164" ref-type="aff">4</xref><xref rid="c1-pharmaceutics-17-00164" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Zeng</surname><given-names>Xiaowei</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00164"><label>1</label>Centro NanoMat, Instituto Polo Tecnol&#x000f3;gico de Pando, Facultad de Qu&#x000ed;mica, Universidad de la Rep&#x000fa;blica, Canelones 91000, Uruguay; <email>acastro@fq.edu.uy</email> (A.C.); <email>rfaccio@fq.edu.uy</email> (R.F.); <email>pmiranda@fq.edu.uy</email> (P.M.); <email>amombru@fq.edu.uy</email> (&#x000c1;.W.M.)</aff><aff id="af2-pharmaceutics-17-00164"><label>2</label>Laboratorio de Glicobiolog&#x000ed;a e Inmunolog&#x000ed;a Tumoral, Institut Pasteur de Montevideo, Montevideo 11400, Uruguay; <email>apittini@pasteur.edu.uy</email> (&#x000c1;.P.); <email>nberois@pasteur.edu.uy</email> (N.B.); <email>eosinaga@pasteur.edu.uy</email> (E.O.)</aff><aff id="af3-pharmaceutics-17-00164"><label>3</label>Departamento de Inmunobiolog&#x000ed;a, Facultad de Medicina, Universidad de la Rep&#x000fa;blica, Montevideo 11800, Uruguay</aff><aff id="af4-pharmaceutics-17-00164"><label>4</label>C&#x000e1;tedra de F&#x000ed;sica, Facultad de Qu&#x000ed;mica, DETEMA, Universidad de la Rep&#x000fa;blica, Montevideo 11800, Uruguay</aff><author-notes><corresp id="c1-pharmaceutics-17-00164"><label>*</label>Correspondence: <email>hpardo@fq.edu.uy</email></corresp><fn id="fn1-pharmaceutics-17-00164"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>164</elocation-id><history><date date-type="received"><day>26</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives</bold>: The focus of this study was to prepare and characterize docetaxel (DCX)-loaded lipid/polymer hybrid nanoparticles (LPHNps) functionalized with the monoclonal antibody (mAb) Chi-Tn for a potential active targeting approach in lung cancer treatment. <bold>Methods</bold>: We synthesized DOTAP-PLGA hybrid nanoparticles loaded with DCX and functionalized them with Chi-Tn mAb through a biotin&#x02013;avidin approach. The physicochemical characterization involved dynamic light scattering, transmission electron microscopy, Raman spectroscopy, and atomic force microscopy. The in vitro and in vivo evaluations encompassed uptake studies, cell viability tests, and the assessment of tumor growth control in a lung cancer model. <bold>Results</bold>: The nanoparticles featured a hydrophobic PLGA core with 99.9% DCX encapsulation efficiency, surrounded by a DOTAP lipid shell ensuring colloidal stability with a high positive surface charge. The incorporation of PEGylated lipids on their surface helps evade the immune system and facilitate Chi-Tn mAb attachment. The resulting nanoparticles exhibit a spherical shape with monodisperse particle sizes averaging 250 nm, and demonstrate sustained drug release. In vitro uptake studies and viability assays conducted in A549 cancer cells show that the Chi-Tn mAb enhances nanoparticle internalization and significantly reduces cell viability. In vivo studies demonstrate a notable reduction in tumor volume and an increased survival rate in the A549 tumor xenograft mice model when DCX was encapsulated in nanoparticles and targeted with Chi-Tn mAb in comparison to the free drug. <bold>Conclusions</bold>: Therefore, Chi-Tn-functionalized LPHNps hold promise as carriers for actively targeting DCX to Tn-expressing carcinomas.</p></abstract><kwd-group><kwd>lipid polymer hybrid nanoparticles</kwd><kwd>active targeting</kwd><kwd>cancer treatment</kwd><kwd>Tn antigen</kwd><kwd>PLGA</kwd><kwd>DOTAP</kwd></kwd-group><funding-group><award-group><funding-source>CAP</funding-source></award-group><award-group><funding-source>ANII</funding-source><award-id>POS_NAC_2015_1_109551</award-id></award-group><funding-statement>Anal&#x000ed;a Castro&#x02019;s work was supported by a postgraduate scholarship from CAP and ANII (POS_NAC_2015_1_109551).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00164"><title>1. Introduction</title><p>Cancer is one of the most important public health problems of the 21st century. In particular, lung cancer was the leading cause of cancer-related morbidity and mortality worldwide in 2022 [<xref rid="B1-pharmaceutics-17-00164" ref-type="bibr">1</xref>]. Despite the availability of various treatments, including surgery, radio-chemotherapy, molecular targeted therapy, and immunotherapy, the five-year survival rate for lung cancer remains below 20% in most countries [<xref rid="B2-pharmaceutics-17-00164" ref-type="bibr">2</xref>]. Consequently, developing new therapies to improve survival rates is crucial.</p><p>Nanotechnology-based drug delivery systems have gained significant attention over the past decades due to their potential to reduce side effects, minimize toxicity, and enhance the efficacy of anticancer treatments [<xref rid="B3-pharmaceutics-17-00164" ref-type="bibr">3</xref>]. The US Food and Drug Administration (FDA) has approved several nanocarriers for clinical use, with polymeric nanoparticles and liposomes being particularly promising because of their biocompatible and biodegradable properties [<xref rid="B4-pharmaceutics-17-00164" ref-type="bibr">4</xref>]. Notable examples of commercially available liposomal antiproliferative drugs include Doxil and Daunoxome, which offer advantages such as increased solubility of the active compound, protection from adverse effects, high biocompatibility due to their similarity to biological membranes, prolonged drug release, and ease of surface modification. However, some drawbacks, such as poor storage stability, limit their broader application [<xref rid="B5-pharmaceutics-17-00164" ref-type="bibr">5</xref>].</p><p>Polymeric nanoparticles are easier to prepare and exhibit high structural integrity, greater stability, and controlled release capability. Nevertheless, they have some disadvantages, including the need for organic solvents in their synthesis, low payload capacity, and moderate half-life in the bloodstream. One of the most widely used biopolymers, approved by the FDA and the European Medicines Agency (EMA), is poly(lactic-co-glycolic acid) (PLGA). PLGA is a versatile synthetic copolymer composed of glycolic acid and lactic acid units, the ratio of which determines some of its properties [<xref rid="B6-pharmaceutics-17-00164" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00164" ref-type="bibr">7</xref>]. It is a biocompatible and biodegradable polymer, and it has been widely studied for the development of drug transport and release systems, such as small molecules, proteins, and other macromolecules, both for research and commercial developments.</p><p>To overcome the limitations of polymeric nanoparticles and liposomes while combining the favorable attributes of both nanosystems, a new generation of lipid/polymer hybrid nanoparticles (LPHNps) has been developed. LPHNps consist of a polymeric core surrounded by a lipid shell. The polymer constituent provides support to the hybrid structure while also being able to encapsulate both hydrophilic and hydrophobic drugs. The lipid portion helps avoid the rapid clearance of nanoparticles by the reticuloendothelial system (RES), can be chemically modified to enable targeted drug delivery, acts as a barrier to mitigate the leakage of entrapped drugs, and protects the core from degradation by preventing the diffusion of water into the inner core [<xref rid="B8-pharmaceutics-17-00164" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00164" ref-type="bibr">9</xref>].</p><p>These nanoparticles, with lipid layers around a polymeric core, can be rapidly prepared using a single-step nanoprecipitation and self-assembly method to achieve high drug-encapsulation efficiency [<xref rid="B10-pharmaceutics-17-00164" ref-type="bibr">10</xref>]. They are mainly composed of (1) PLGA as a hydrophobic core for encapsulating hydrophobic drugs, such as DCX, a chemotherapeutic agent with a wide spectrum of anti-tumor activity; (2) lipid 1,2-Dioleoyloxy-3-trimethylammonium-propane chloride (DOTAP-Cl) as a cationic lipid layer surrounding the PLGA core; and (3) 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol (DSPE-PEG) and DSPE-PEG-Biotin serve as polyethylene glycol (PEG) outer layer that incorporates into the lipid shell, extending the in vivo circulation half-life and offering functionalization groups for attaching targeting ligands.</p><p>Extensive research has revealed the critical role of glycan alteration in cancer therapy [<xref rid="B11-pharmaceutics-17-00164" ref-type="bibr">11</xref>]. The identification of cancer-specific glycan biomarkers by monoclonal antibodies can be used to discriminate between tumor and normal cells, improving the specificity of tumor treatments [<xref rid="B12-pharmaceutics-17-00164" ref-type="bibr">12</xref>]. The Tn antigen (GalNAc-O-Serine/Threonine) is considered a cryptic marker, typically not found in normal cells as it is masked by other sugar residues on mature glycan chains [<xref rid="B13-pharmaceutics-17-00164" ref-type="bibr">13</xref>]. Tn is one of the most prevalent and specific tumor-associated antigens identified to date [<xref rid="B14-pharmaceutics-17-00164" ref-type="bibr">14</xref>], making it a promising target for cancer diagnosis and immunotherapy. Based on the specificity of murine mAb 83D4 for the Tn antigen generated by our group [<xref rid="B15-pharmaceutics-17-00164" ref-type="bibr">15</xref>], we produced a chimeric mouse/human antibody that retains the Tn binding activity [<xref rid="B15-pharmaceutics-17-00164" ref-type="bibr">15</xref>]. This chimeric anti-Tn mAb (Chi-Tn) selectively binds to a diverse range of carcinomas without exhibiting any affinity for normal tissues [<xref rid="B16-pharmaceutics-17-00164" ref-type="bibr">16</xref>]. It has also been shown to internalize cancer cells and deliver cytotoxic drugs actively [<xref rid="B17-pharmaceutics-17-00164" ref-type="bibr">17</xref>]. To the best of our knowledge, there is currently no study that has yet developed cationic LPHNp functionalized with anti-Tn mAb.</p><p>In previous work, we developed chitosan nanocapsules loaded with DCX and functionalized with Chi-Tn antibodies [<xref rid="B18-pharmaceutics-17-00164" ref-type="bibr">18</xref>]. However, these systems have certain limitations for broader use, particularly because chitosan is not a generally FDA-approved polymer for human applications. This distinction in composition highlights a significant innovation, as PLGA-based nanoparticles offer enhanced biocompatibility and greater potential for clinical translation compared to chitosan-based systems.</p><p>Considering the potential of LPHNp and the promising results previously obtained with DCX-loaded chitosan nanocapsules functionalized with Chi-Tn mAb [<xref rid="B18-pharmaceutics-17-00164" ref-type="bibr">18</xref>], we propose that PLGA-DOTAP hybrid immunonanoparticles could serve as a novel and enhanced drug delivery platform for lung cancer treatment. In this study, we developed, characterized, and evaluated a novel DCX-loaded DOTAP-PLGA hybrid nanoparticle conjugated with Chi-Tn mAb as a potential cancer treatment. This formulation demonstrated high drug encapsulation efficiency and the active targeting of tumor cells, exhibiting enhanced anti-tumor activity in both in vitro and in vivo human lung cancer models.</p></sec><sec id="sec2-pharmaceutics-17-00164"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00164"><title>2.1. Materials</title><p>Poly(<sc>d,l</sc>-lactic-<italic toggle="yes">co</italic>-glycolic acid), PLGA, 50:50 Resomer RG 502 H, molecular weight (Mw) 7000&#x02013;17,000 g/mol, was purchased from Evonik (Buenos Aires, Argentina). The cationic lipid 1,2-Dioleoyl-3-trimethylammonium-chloride (DOTAP-Cl) was obtained from Lipoid (Steinhausen, Switzerland). Docetaxel, with a purity greater than 99%, was acquired from Alfa Aesar (Tewksbury, MA, USA). Crodamol GTCC, a blended ester made from caprylic and capric acids, was sourced from Croda (Buenos Aires, Argentina). 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly-ethylene glycol (DSPE-PEG, Mw 2 KDa) and DSPE-PEG-Biotin (Mw 2 KDa) were purchased from Broadpharma (San Diego, CA, USA). Poloxamer 188 and Avidin from egg white (&#x02265;10 units/mg protein) were purchased from Sigma Aldrich (St. Louis, MO, USA). All the other reagents used were of analytical grade.</p></sec><sec id="sec2dot2-pharmaceutics-17-00164"><title>2.2. Cells Lines and Animals</title><p>A549 cells (purchased from American Type Culture Collection&#x02014;ATCC, Manassas, VA, USA, catalog number CCL-185/RRID:CVCL_0023), derived from human lung carcinoma, were grown in Dulbecco&#x02019;s modified Eagle&#x02019;s Medium enriched with 10% fetal bovine serum and 1% glutamine. The cells were incubated at 37 &#x000b0;C in a humidified atmosphere containing 5% CO<sub>2</sub>.</p><p>Twenty-five female mice (<italic toggle="yes">Mus musculus nude</italic>) (26 &#x000b1; 2 g, 6&#x02013;8 weeks old) were bred by the Laboratory Animal Biotechnology Unit of the Institute Pasteur of Montevideo, Uruguay. All the animal experiments were conducted in accordance with the Ethics Committee on Animal Use at the Institut Pasteur of Montevideo (approval number 003-22), following the ARRIVE guidelines. The animals were housed in a controlled environment free of specific pathogens (SPF), with temperatures maintained between 19 and 21 &#x000b0;C, and a 14 h light/10 h dark cycle. The mice were provided with sterile food and water ad libitum. In this study, the only procedures performed on the mice were subcutaneous and intraperitoneal injections, which caused minimal discomfort, so anesthesia was not required. At the conclusion of the experiment, the mice were euthanized using 100% CO<sub>2</sub>.</p></sec><sec id="sec2dot3-pharmaceutics-17-00164"><title>2.3. Preparation of LPHNps</title><p>The preparation of nanoparticles was carried out through the self-assembly of lipid and polymeric components using the nanoprecipitation method resulting from the modification and combination of the protocols reported by Bose et al. [<xref rid="B19-pharmaceutics-17-00164" ref-type="bibr">19</xref>], Dai et al. [<xref rid="B20-pharmaceutics-17-00164" ref-type="bibr">20</xref>], and Klippstein et al. [<xref rid="B21-pharmaceutics-17-00164" ref-type="bibr">21</xref>]. Specifically, 100 mg of PLGA was dissolved in 5.4 mL of acetone, which was then mixed with 0.5 mL of ethanol containing 7.5 mg of DOTAP, 5 mg of DSPE-PEG, 2.5 mg of DSPE-PEG-Biotin, and 125 &#x000b5;L of crodamol. This organic phase was divided into two equal portions. To one of the parts, 500 &#x000b5;L of a DCX stock solution (40 mg/mL in acetone) was added, resulting in drug-loaded nanoparticles (LPHNp-DCX), while the other half was added with 500 &#x000b5;L of acetone to subsequently obtain empty nanoparticles (LPHNps).</p><p>On the other hand, 50 mg of poloxamer 188 was dissolved in 10 mL of water; this aqueous phase was also divided into equal portions. Both were placed on heating plates until reaching a final temperature of 50 &#x000b0;C. Subsequently, the organic phase was slowly added dropwise to its respective aqueous phase under vigorous stirring. The resulting suspension was stirred for at least 2 h to allow self-assembly and ensure organic solvent removal. Finally, if necessary, the volume was adjusted to 5 mL. This way, nanoparticles with a final concentration of 4 mg of DCX/mL were obtained.</p><p>Fluorescent nanoparticles were prepared in the same manner as those loaded with DCX, replacing DCX with the fluorescent probe Coumarin-6 (adding 1 mL of an ethanolic solution of coumarin with a concentration of 0.2 mg/mL).</p></sec><sec id="sec2dot4-pharmaceutics-17-00164"><title>2.4. Functionalization of LPHNp with Chi-Tn mAb</title><p>LPHNp-Chi-Tn mAb was prepared by a two-step conjugation process involving pegylated nanoparticles and biotinylated Chi-Tn mAb utilizing the avidin&#x02013;biotin interaction. In the first step, 10.8 &#x000b5;L of an avidin solution (2 mg/mL) was added to 2 mL of LPHNp. The mixture was then shaken in the dark for 1 h at room temperature. Following this, 48 &#x000b5;L of a biotinylated Chi-Tn mAb solution (1 mg/mL) was incorporated into the mixture, and shaking continued overnight. After these two incubation steps, the DCX-loaded LPHNp-anti-Tn antigen formulations were successfully obtained.</p><p>The attachment of the antibody to the nanoparticles was confirmed through an indirect ELISA combined with fluorescence measurements. Initially, ELISA plates were sensitized with the asialo ovine submaxillary mucin (aOSM), which contains the Tn antigen, and were incubated with the fluorescent LPHNp-Coumarin-ChiTn mAb. Subsequently, incubation with an HRP-conjugated secondary antibody was performed. Fluorescence intensity measurements confirmed the presence of the nanoparticles, while the binding of the secondary antibody demonstrated that the ChiTn mAb maintained its functionality after attaching to the nanoparticles.</p></sec><sec id="sec2dot5-pharmaceutics-17-00164"><title>2.5. Nanoparticle Characterization</title><sec id="sec2dot5dot1-pharmaceutics-17-00164"><title>2.5.1. Particle Size and Zeta Potential</title><p>The hydrodynamic diameter and zeta potential of the samples were determined using a particle size/zeta potential analyzer (Nano-ZS, Malvern Instruments Ltd., Malvern, Worcestershire, UK). Measurements were performed in an aqueous medium at 25 &#x000b0;C, with a viscosity of 0.8872 cP and a refractive index of 1.33. Particle size was evaluated using dynamic light scattering (DLS) and reported as the z-average, while zeta potential was calculated from the electrophoretic mobility using the Helmholtz&#x02013;Smoluchowski equation. Each sample was analyzed in triplicate, and the results are presented as mean &#x000b1; standard deviation (S.D.).</p></sec><sec id="sec2dot5dot2-pharmaceutics-17-00164"><title>2.5.2. Surface Morphology</title><p>The morphology of the nanocarriers was examined using high-resolution transmission electron microscopy (HRTEM) with an HR-STEM JEOL 2100 microscope (Jeol Ltd., Tokyo, Japan). The samples were stained with a 2% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) uranyl acetate solution, placed on a carbon film-covered copper grid (300-mesh), and air-dried for 24 h before scanning.</p></sec><sec id="sec2dot5dot3-pharmaceutics-17-00164"><title>2.5.3. Raman Spectroscopy </title><p>The formation of hybrid nanoparticles was examined using confocal Raman spectroscopy, performed with a WITec Alpha 300-RA Raman-Confocal Microscope (WITec GmbH, Ulm, Germany). PLGA, DOTAP, DSPE-PEG, DSPE-PEG-Biotin, crodamol, and LPHNp were analyzed. All the samples were placed on a silicon wafer and the nanoparticle aqueous suspension was dried under a stream of nitrogen before measurement.</p></sec><sec id="sec2dot5dot4-pharmaceutics-17-00164"><title>2.5.4. Atomic Force Microscopy</title><p>LPHNps were examined through atomic force microscopy (AFM) in tapping mode using a WITec Alpha 300-RA AFM Microscope (WITec GmbH, Ulm, Germany). The AFM data were acquired by depositing a droplet of the nanoparticle suspension onto a silicon wafer substrate, and the sample was subsequently dried under a stream of nitrogen.</p></sec><sec id="sec2dot5dot5-pharmaceutics-17-00164"><title>2.5.5. Encapsulation Efficiency of DCX-Loaded Nanoparticles</title><p>The encapsulation efficiency (EE%) of DCX within LPHNp was calculated indirectly by subtracting the amount of free drug in the supernatant from the total amount of DCX in the formulation. For this process, the nanoparticles were centrifuged in Amicon tubes (10 KDa) at 4000&#x000d7; <italic toggle="yes">g</italic> for 15 min, and the concentration of free DCX was measured using high-performance liquid chromatography (HPLC). The HPLC system consisted of a Thermo Scientific Ultimate 3000, equipped with a UV detector set at 232 nm, and coupled with a reverse-phase Zorbax Extend 300 C18 column (4.6 mm &#x000d7; 150 mm i.d., 3.5 &#x003bc;m pore size, Agilent, Santa Clara, CA, USA). The standard calibration curves for DCX demonstrated excellent linearity (r<sup>2</sup> &#x0003e; 0.999) across a concentration range of 0.1&#x02013;1.4 &#x003bc;g/mL.</p></sec><sec id="sec2dot5dot6-pharmaceutics-17-00164"><title>2.5.6. In Vitro Drug Release Study</title><p>The in vitro release profile of DCX from the nanoparticles was determined using a dynamic dialysis method. In summary, 0.5 mL of the sample was placed into a dialysis bag (cutoff 2 KDa) and dialyzed against PBS (pH 7.4) and acetate buffer (pH 5), both containing 0.5% Tween-80. This setup simulated physiological conditions and intracellular release behaviors. The dialysis bag was stirred at 120 rpm, and the temperature was kept constant at 37 &#x000b0;C. At specified time intervals, 1 mL of dialysate was withdrawn and immediately replaced with a fresh medium to ensure sink conditions. The drug concentration was then analyzed using HPLC.</p></sec><sec id="sec2dot5dot7-pharmaceutics-17-00164"><title>2.5.7. Short-Term Stability Testing </title><p>Stability is an essential aspect that influences the performance and efficacy of LPHNp formulations. For stability evaluation, three batches from each group (blank LPHNp, LPHNp-DCX, and LPHNp-DCX-Chi-Tn mAb) were kept at 4 &#x000b0;C for 27 days. DLS was employed to assess stability, with particle size measurements taken at specified time intervals.</p></sec></sec><sec id="sec2dot6-pharmaceutics-17-00164"><title>2.6. In Vitro Cell Test</title><sec id="sec2dot6dot1-pharmaceutics-17-00164"><title>2.6.1. Cell Uptake Studies</title><p>The A549 cells were grown on coverslips within a 24-well plate at a density of 1 &#x000d7; 10<sup>5</sup> cells/well for 24 h. Subsequently, the medium was replaced with the treatment solution: LPHN-Coumarin and LPHN-Coumarin-ChiTn mAb. After a 30 min incubation, the cells were washed twice with PBS and fixed with 4% paraformaldehyde. The nuclei were stained with DAPI (4&#x02032;,6-diamidino-2-phenylindole) at a concentration of 1 &#x003bc;g/mL for 1&#x02013;2 min at room temperature, followed by washing. The cells were then mounted and examined using a Zeiss LSM 800 (Zeiss, Oberkochen, Germany) confocal laser scanning microscope. For flow cytometry internalization studies, the same protocol as mentioned above was followed. The A549 cells were collected, centrifuged at 300&#x000d7; <italic toggle="yes">g</italic> for 10 min, and re-suspended in PBS (pH 7.4). The samples were acquired using a BD Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA, USA).</p></sec><sec id="sec2dot6dot2-pharmaceutics-17-00164"><title>2.6.2. Cell Viability Assay</title><p>The cells were plated in a 96-well plate at a density of 5 &#x000d7; 10<sup>3</sup> cells/well. Once they reached confluence, 10 &#x000b5;L of the treatments&#x02014;DCX, LPHNp-DCX, LPHNp-DCX-Chi-Tn mAb, and blank LPHNp&#x02014;were added at various concentrations (0.19, 0.39, 0.78, 1.56, 3.125, 6.25, and 12.5 &#x000b5;g/mL). After 72 h of incubation, 10 &#x000b5;L of CCK-8 solution was introduced to each well, followed by an additional 1 h incubation at 37 &#x000b0;C. The absorbance was then measured at 450 nm using a microplate reader. Cell viability was calculated as a percentage compared to the control (untreated) cells.</p></sec></sec><sec id="sec2dot7-pharmaceutics-17-00164"><title>2.7. In Vivo Studies</title><p>All the experiments involving animals were conducted in accordance with the local regulations and were approved by the Ethics Committee on Animal Use of Institut Pasteur of Montevideo. A total of 25 female mice (Mus musculus <italic toggle="yes">nude</italic>) aged eight to ten weeks were injected subcutaneously with 1 &#x000d7; 10<sup>6</sup> A549 tumor cells in the left flank. To monitor progression, the tumors were measured every 3 days using a caliper, and tumor volume was calculated using the formula V = (D&#x000b7;d<sup>2</sup>)/2, where D and d represent the longest and shortest tumor diameters, respectively. Once the tumors reached a volume of approximately 100 mm<sup>3</sup>, the mice were randomized into five treatment groups (n = 4&#x02013;5 per group). The experimental groups received intraperitoneal injections of PBS as a negative control, free DCX (Taxotere), empty LPHNp&#x02013;ChiTn mAb, LPHNp-DCX, and LPHNp-DCX-ChiTn mAb, each at a dose of 10 mg DCX/kg. Treatments were administered three times every four days. The endpoint of the study was set at 100 days post-tumor cell inoculation or when the tumor volume reached 1500 mm<sup>3</sup>, whichever occurred first. At this stage, the animals were euthanized using 100% CO<sub>2</sub>.</p></sec><sec id="sec2dot8-pharmaceutics-17-00164"><title>2.8. Statistical Analysis </title><p>The in vitro experiments were conducted in triplicate, and the results are presented as mean &#x000b1; SD. The quantitative values were analyzed using one- and two-way analysis of variance (ANOVA), followed by post hoc tests including Tukey and Bonferroni. The tumor volume analysis involved one-way ANOVA followed by Tukey&#x02019;s post-test. Survival analyses were performed using the Log-rank (Mantel&#x02013;Cox) test. The Prism software package (version 8.00; GraphPad Software, San Diego, CA, USA) was used to perform the statistical tests. Significant differences are denoted by asterisks (*, <italic toggle="yes">p</italic> &#x0003c; 0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01; ***, <italic toggle="yes">p</italic> &#x0003c; 0.001; ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001).</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00164"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00164"><title>3.1. Synthesis and Characterization of Nanoparticles</title><p>In the current study, we employed PLGA as a representative hydrophobic polymer to serve as the foundational polymeric core for the nanoparticles, enabling the efficient encapsulation of a substantial quantity of DCX. Additionally, we introduced PEG conjugated to DSPE as a dual-purpose strategy: firstly, to extend the circulation lifespan of the nanoparticles within the bloodstream, and secondly, to act as a ligand for surface functionalization of the nanoparticles. Lastly, we utilized DOTAP-Cl as a prototypical lipid compound, facilitating the formation of a lipid monolayer at the interface between the PLGA core and the PEG shell. Since the FDA has approved PLGA and DSPE-PEG for medical applications, and DOTAP is a synthetic lipid with extensive preclinical and clinical trials toxicity data [<xref rid="B22-pharmaceutics-17-00164" ref-type="bibr">22</xref>], we expect the LPHNp obtained should be biocompatible, biodegradable, and potentially safe as a drug carrier for clinical use.</p><p>The LPHNps were prepared using a modified version of the single-step nanoprecipitation method previously reported by Bose et al. [<xref rid="B19-pharmaceutics-17-00164" ref-type="bibr">19</xref>], Dai et al. [<xref rid="B20-pharmaceutics-17-00164" ref-type="bibr">20</xref>], and Klippstein et al. [<xref rid="B21-pharmaceutics-17-00164" ref-type="bibr">21</xref>]. More specifically, the organic phase containing all the constituents, including lipids, polymers, and drugs, was gradually introduced into an aqueous phase containing a hydrophilic surfactant. The mixing of the aqueous and organic phases resulted in spontaneous emulsion, and the polymer core particles formed as a consequence of PLGA precipitation. Additionally, the DOTAP and DSPE-PEG conjugates self-assembled around the PLGA core to form a lipid monolayer covered by a PEG shell.</p><p>To examine the intermolecular interactions inherent in the nanocomplex formation, Raman spectra were obtained from solutions comprising individual as well as combined components. In <xref rid="pharmaceutics-17-00164-f001" ref-type="fig">Figure 1</xref>, the Raman spectra of DSPE-PEG (a), DSPE-PEG-Biotin (b), PLGA (c), LPHNPs (d), DOTAP-Cl (e), and crodamol (f) are displayed. The most distinctive features of lipids in Raman spectroscopy are contingent upon alkyl tails. Specifically, the vibrational stretching mode of unsaturated =CH is clearly observed at 3008 cm&#x0207b;<sup>1</sup>, while CH<sub>2</sub> Fermi resonance and symmetric stretching bands appear in the range of 2848&#x02013;2880 cm&#x0207b;<sup>1</sup>. The C=O ester, C=C, and C&#x02013;C stretching modes exhibit bands at approximately 1743 cm&#x0207b;<sup>1</sup>, 1657 cm&#x0207b;<sup>1</sup>, and 1090 cm&#x0207b;<sup>1</sup>, respectively. CH<sub>2</sub> scissoring and twisting and =C&#x02013;H in-plane deformation are situated in the range of 1232&#x02013;1483 cm&#x0207b;<sup>1</sup> [<xref rid="B23-pharmaceutics-17-00164" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-17-00164" ref-type="bibr">24</xref>]. In the case of DOTAP, additional bands appear at around 970, and 761 cm&#x0207b;<sup>1</sup>, corresponding to the trimethylammonium group [<xref rid="B25-pharmaceutics-17-00164" ref-type="bibr">25</xref>]. In the case of PLGA, based on previous works, the peaks detected are ascribable to the vibrational modes of the lactic (LA) or/and glycolic (GA) units. There are characteristic peaks for CH<sub>2</sub> (2880 cm<sup>&#x02212;1</sup>), CH<sub>3</sub> (2949 cm<sup>&#x02212;1</sup>), and carbonyl (C=O, 1771 cm<sup>&#x02212;1</sup>) bonds [<xref rid="B26-pharmaceutics-17-00164" ref-type="bibr">26</xref>].</p><p>Discrepancies in the characteristic peaks previously defined for PLGA and lipids were discernible in the Raman spectra of LPHNp. These outcomes corroborated the establishment of a PLGA-lipid complex, facilitated by the hydrophobic interaction of alkyl tails and/or ester group of the hydrophobic features, as well as the ionic interactions between the carboxylic groups of PLGA and the trimethylammonium group of DOTAP.</p><p>LPHNp exhibited a monodisperse population with an average particle size of less than 250 nm and a significantly high positive surface charge (<xref rid="pharmaceutics-17-00164-t001" ref-type="table">Table 1</xref>). Positively charged nanoparticles have demonstrated greater cellular internalization efficiency compared to neutral or negatively charged nanoparticles [<xref rid="B27-pharmaceutics-17-00164" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00164" ref-type="bibr">28</xref>]. However, they face significant stability challenges in biological fluids due to their interactions with negatively charged biomolecules, which can lead to aggregation, protein corona formation, and rapid clearance. In our study, the incorporation of PEGylated lipids onto the surface of LPHNp addresses these challenges by providing a steric barrier that reduces unspecific interactions with plasma proteins and cells, as supported by the literature [<xref rid="B29-pharmaceutics-17-00164" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00164" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-00164" ref-type="bibr">31</xref>]. The positive charge of these nanoparticles arises from the cationic lipid monolayer coating the hydrophobic polymeric core composed of PLGA and crodamol oil. Surface charge plays a pivotal role in determining the stability of colloidal nanoparticle systems, with repulsive forces between similarly charged nanoparticles enhancing stability.</p><p>DCX, a highly water-insoluble compound, exhibits a strong affinity for the hydrophobic core of these LPHNp. This feature enables a remarkable encapsulation efficiency (EE) of 99.92% for DCX, resulting in a final loading of 4 mg DCX/mL, which is much higher than the encapsulation efficiency reported by other groups for PLGA nanoparticles. For instance, Gupta et al. [<xref rid="B32-pharmaceutics-17-00164" ref-type="bibr">32</xref>] developed DCX-loaded PEGylated PLGA nanoparticles loaded with an average size of 150 nm and an EE of 70%. Meanwhile, Zhang et al. [<xref rid="B33-pharmaceutics-17-00164" ref-type="bibr">33</xref>] prepared LPHNp using PLGA and lecithin, also loaded with DCX, but achieved an EE of less than 60%. Both studies utilized a total DCX concentration significantly lower than that used in our system. Achieving high encapsulation efficiency is critical in drug delivery systems, as it reduces the amount of nanoparticles needed to deliver specific doses of active agents. This strategy not only minimizes potential nanoparticle-related side effects but also enhances therapeutic efficacy and lowers overall production costs.</p><p>To produce LPHNp functionalized with Chi-Tn mAb, our focus was on the non-covalent interaction inherent in avidin&#x02013;biotin binding. In this process, LPHNps, which present a biotin motif on their surface, were initially incubated with tetrameric avidin, followed by subsequent incubation with biotinylated Chi-Tn mAb. This strategy, with documented advantages in prior studies [<xref rid="B34-pharmaceutics-17-00164" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00164" ref-type="bibr">35</xref>], provides precise control over the placement and density of the ligand on the nanoparticle surface, ensuring efficient ligand&#x02013;receptor interactions. As expected, the encapsulation of DCX and the functionalization with the Chi-Tn antibody had little effect on the size and charge of the blank LPHNp.</p><p>The morphology of the nanosystems was examined using high-resolution transmission electron microscopy before staining with 2% uranyl acetate solution, which stains lipid structures to enhance their electron density. The TEM images of LPHNp-DCX-Chi-Tn mAb are shown in <xref rid="pharmaceutics-17-00164-f002" ref-type="fig">Figure 2</xref>. The lipid/polymer nanocarriers exhibit a spherical shape and a size close to 200 nm (<xref rid="pharmaceutics-17-00164-f002" ref-type="fig">Figure 2</xref>), a result that corresponds to that observed by DLS. Notably, this size falls within the optimal range of 70 to 300 nm, as reported in the literature, which is considered ideal for enhancing biological performance [<xref rid="B36-pharmaceutics-17-00164" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00164" ref-type="bibr">37</xref>]. The thickness of the lipidic ring surrounding the PLGA core is less than 5 nm, which could correspond to a lipid monolayer plus PEG shell.</p><p>LPHNps were further examined by AFM to provide more information about surface morphology and particle size. In <xref rid="pharmaceutics-17-00164-f002" ref-type="fig">Figure 2</xref>, both the 2D and 3D AFM images illustrate alterations in surface topography, indicating the presence of nanoparticles with a spherical shape. A preliminary assessment of the peaks from the AFM topography analysis revealed that the nanoparticles exhibited a particle size of 250 nm, aligning with the data obtained from the TEM and DLS.</p></sec><sec id="sec3dot2-pharmaceutics-17-00164"><title>3.2. In Vitro Drug Release and Storage Stability Test</title><p>The in vitro release profile of DCX from the hybrid nanoparticles under different conditions, pH 5 (which mimics the acidic environment found in the endosomes or tumor microenvironment) and pH 7.4 (representing the physiological conditions in the blood), is illustrated in <xref rid="pharmaceutics-17-00164-f003" ref-type="fig">Figure 3</xref>A. The presence of Tween-80 in the buffer solution can facilitate the release of DCX from the matrix polymer, as previously reported [<xref rid="B38-pharmaceutics-17-00164" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-17-00164" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-00164" ref-type="bibr">40</xref>]. The nanoparticles exhibited sustained drug release behavior for up to 48 h, with a nearly identical pattern in both pH media but higher at pH 5 compared to pH 7.4. The release kinetics followed a zero-order model with a correlation coefficient (r<sup>2</sup>) of 0.9915 for pH 7.4 and 0.9877 for pH 5.</p><p>The stability of nanocarriers is a crucial factor for their storage and functionality in long-term biomedical applications. To assess the shelf life of the formulations, three batches of each group&#x02014;LPHNp, LPHNp-DCX, and LPHNp-DCX-Chi-Tn mAb&#x02014;were stored at 4 &#x000b0;C. The z-average, representing the average intensity-weighted diameters, was employed to investigate the stability of LPHNps through dynamic light scattering (DLS) measurements at various time intervals. As depicted in <xref rid="pharmaceutics-17-00164-f003" ref-type="fig">Figure 3</xref>B, all the samples stored at 4 &#x000b0;C remained stable for 27 days, exhibiting a uniform appearance without any visible signs of instability, such as sedimentation or aggregation.</p></sec><sec id="sec3dot3-pharmaceutics-17-00164"><title>3.3. Cell Uptake Study</title><p>In order to study the uptake of LPHNp by the A549 cancer cell line, a fluorescent dye was encapsulated, and its uptake was observed using confocal microscopy. For this purpose, 6-coumarin was loaded into LPHNp, with or without the Chi-Tn mAb, and then incubated at 37 &#x000b0;C or 4 &#x000b0;C as a negative control for endocytosis. As shown in <xref rid="pharmaceutics-17-00164-f004" ref-type="fig">Figure 4</xref>, the confocal microscopy images revealed that at 4 &#x000b0;C, the nanoparticles were primarily located outside the cell or associated with the cell surface (<xref rid="pharmaceutics-17-00164-f004" ref-type="fig">Figure 4</xref>B,C). In contrast, at 37 &#x000b0;C, the LPHNps were fully internalized by A549, appearing to be within vesicles (<xref rid="pharmaceutics-17-00164-f004" ref-type="fig">Figure 4</xref>E,F). This indicates that the encapsulated dye was likely internalized by the cell through an endocytic mechanism. Additionally, the images showed that the association of 6-coumarin LPHNps with A549 cells seems to be enhanced by the presence of Chi-Tn mAb.</p><p>Flow cytometry supported the qualitative findings of the CLSM studies. The results demonstrated that the A549 cell line efficiently internalized LPHNps, leading to an increase in both the percentage of 6-coumarin-LPHNp+ cells (<xref rid="pharmaceutics-17-00164-f004" ref-type="fig">Figure 4</xref>G) and 6-coumarin-LPHNp mean fluorescence intensity (MFI) (<xref rid="pharmaceutics-17-00164-f004" ref-type="fig">Figure 4</xref>H) compared to the untreated cells and A549 cells incubated at 4 &#x000b0;C, serving as a control to minimize active internalization. This finding confirms that the Chi-Tn antibody enhances cellular internalization, these findings align with the prior results from our group, where Chi-Tn mAb demonstrated rapid internalization across multiple cancer cell lines and was observed within early and recycling endosomes [<xref rid="B17-pharmaceutics-17-00164" ref-type="bibr">17</xref>].</p></sec><sec id="sec3dot4-pharmaceutics-17-00164"><title>3.4. Cell Viability Assay</title><p>To evaluate the cytotoxicity of the obtained LPHNps and free DCX, a CCK-8 colorimetric cell viability assay was performed on the A549 human lung cancer cell line. The cells were incubated with LPHNp-DCX, LPHNp-DCX-Chi-Tn, free DCX, and blank LPHNp for 24, 48, and 72 h at concentrations ranging from 0.19 to 12.5 &#x000b5;g/mL. The results, depicted in <xref rid="pharmaceutics-17-00164-f005" ref-type="fig">Figure 5</xref>, demonstrate that LPHNps loaded with DCX significantly reduce the cell viability of the A549 cells compared to free DCX at 24 and 48 h of incubation. However, this difference becomes less pronounced at 72 h. This may be due to the accelerated uptake of the encapsulated DCX in the nanosystems and the consequent release of the drug into the cytosolic space. Moreover, the Chi-Tn antibody-functionalized LPHNps further enhances this antiproliferative response in the A549 cells, showing a significant difference compared to both LPHNp-DCX and free DCX. This suggests that the antibody enhances the internalization of the nanosystems, an observation supported by cellular uptake studies. Conversely, blank LPHNp carriers showed no impact on cell growth.</p></sec><sec id="sec3dot5-pharmaceutics-17-00164"><title>3.5. In Vivo Anti-Tumor Activity</title><p>In order to evaluate the anti-tumor effects of DCX loaded in Chi-Tn mAb-functionalized LPHNp in an in vivo model, A549 human lung cancer cells were subcutaneously injected into the flank of <italic toggle="yes">nude</italic> mice to establish xenotransplants. The animals were then subjected to various treatments: PBS (control group), free DCX, empty LPHNp&#x02013;Chi-Tn mAb, LPHNp-DCX, and LPHNp-DCX-Chi-Tn mAb, administered in three doses of 10 mg DCX/kg each, every four days. The tumor volume and survival rate were measured to evaluate the impact of the different treatments. As expected, the animals treated with PBS exhibited the most significant tumor growth and the lowest survival rate (<xref rid="pharmaceutics-17-00164-f006" ref-type="fig">Figure 6</xref>A,B). Conversely, the animals treated with LPHNp-DCX-Chi-Tn displayed the least tumor growth and the highest survival rate. In addition, both LPHNp-DCX and LPHNp-Chi-Tn also decreased tumor growth similarly to LPHNp-DCX-Chi-Tn; indeed, no significant differences were observed among these treatment groups. Furthermore, all the nanoparticle formulations demonstrated a significant decrease in tumor growth compared to the commercial Taxotere formulation (free DCX), resulting also in a higher survival rate. However, the unique treatment that significantly enhanced the survival rate compared to DCX was the LPHNp-DCX-Chi-Tn preparation. None of the formulated preparations had any observed adverse effects on the body weight of the mice, indicating that the dose of DTX or the formulated preparations administered were well tolerated (<xref rid="pharmaceutics-17-00164-f006" ref-type="fig">Figure 6</xref>C). The improved efficacy of the encapsulated DCX could be attributed to the rapid internalization of the nanoparticles, facilitating intracellular drug delivery, which is in agreement with the in vitro cytotoxicity studies. However, anti-tumor activity is also observed in LPHNp-Chi-Tn, an effect that is logically attributed to the Chi-Tn antibody. Previous research has demonstrated that this antibody triggers antibody-dependent cellular cytotoxicity (ADCC) [<xref rid="B16-pharmaceutics-17-00164" ref-type="bibr">16</xref>]. This implies that the Chi-Tn antibody does not directly exert cytotoxic effects on tumor cells in vitro or in vivo; instead, its action is based on activating the immune system to attack tumor cells. By recognizing the Tn antigen present in tumor cells, this antibody flags them for destruction by effector immune cells possessing Fc receptors (Fc&#x003b3;R), such as macrophages, neutrophils, and NK cells. It is worth noting that the mice used as animal models in this study are immunocompromised due to genetic mutations affecting thymic functionality, resulting in a lack of mature T cells. However, they retain other components of the immune system, primarily macrophages and NK cells, which may contribute to the observed anti-tumor response [<xref rid="B41-pharmaceutics-17-00164" ref-type="bibr">41</xref>]. These findings suggest that LPHNp could serve as excellent vehicles for drug delivery and release at the target site, either through passive targeting mechanisms exploiting the enhanced permeability and retention effect (EPR) or through active targeting via conjugation with the Chi-Tn mAb, which can also enhance the anti-tumor response via the ADCC mechanism.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-00164"><title>4. Conclusions</title><p>In this study, we developed DCX-loaded LPHNp functionalized with the Chi-Tn antibody, proposing it as an innovative active targeting drug delivery system for lung cancer therapy. The implementation of LPHNp achieved nanocarriers with a high DCX content, exhibiting sustained drug release kinetics. Moreover, DCX-loaded LPHNps-Chi-Tn mAb can internalize into the A549 cell cytoplasm and decrease cell viability more efficiently than non-functionalized nanoparticles or the free drug. Furthermore, the nanoparticle formulations demonstrated more effective anti-tumor activity in vivo compared to the commercial Taxotere formulation (free DCX), resulting in a higher survival rate. These results suggest that LPHNp-Chi-Tn mAb could be utilized as active targeting nanocarriers with controlled drug release to enhance oncological treatments and minimize secondary effects.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors sincerely appreciate the assistance provided by Iris Miraballes from the Laboratorio de Biotecnolog&#x000ed;a at the Instituto Polo Tecnol&#x000f3;gico de Pando (Facultad de Qu&#x000ed;mica, Pando, Uruguay) with the zetasizer measurements. We also gratefully acknowledge the financial support from the CAP and ANII (POS_NAC_2015_1_109551) postgraduate scholarship, which supported the work of Anal&#x000ed;a Castro.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>A.C.: investigation, conceptualization and design, methodology, data analysis, and writing of the original draft. &#x000c1;.P.: investigation, methodology, data analysis, and draft editing. N.B.: conceptualization, investigation, methodology, and draft editing. R.F.: methodology and data analysis. P.M.: investigation and methodology. &#x000c1;.W.M.: conceptualization and supervision. E.O.: conceptualization, project administration, resources, supervision, review, and draft editing. H.P.: conceptualization, project administration, resources, supervision, review, and draft editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All the animal experiments were conducted in accordance with the Ethics Committee on Animal Use at the Institut Pasteur of Montevideo, Uruguay (approval number 003-22), following the ARRIVE guidelines. The animals were used to evaluate the anti-tumor effect of the nanoparticles loaded with DCX, which is essential for a more comprehensive characterization of the formulation.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The characterization data and experimental protocols for this work are available within this manuscript, or from the corresponding author upon request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00164"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bray</surname><given-names>F.</given-names></name>
<name><surname>Laversanne</surname><given-names>M.</given-names></name>
<name><surname>Sung</surname><given-names>H.</given-names></name>
<name><surname>Ferlay</surname><given-names>J.</given-names></name>
<name><surname>Siegel</surname><given-names>R.L.</given-names></name>
<name><surname>Soerjomataram</surname><given-names>I.</given-names></name>
<name><surname>Jemal</surname><given-names>A.</given-names></name>
</person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J. Clin.</source><year>2024</year><volume>74</volume><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00164"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allemani</surname><given-names>C.</given-names></name>
<name><surname>Matsuda</surname><given-names>T.</given-names></name>
<name><surname>Di Carlo</surname><given-names>V.</given-names></name>
<name><surname>Harewood</surname><given-names>R.</given-names></name>
<name><surname>Matz</surname><given-names>M.</given-names></name>
<name><surname>Nik&#x00161;i&#x00107;</surname><given-names>M.</given-names></name>
<name><surname>Bonaventure</surname><given-names>A.</given-names></name>
<name><surname>Valkov</surname><given-names>M.</given-names></name>
<name><surname>Johnson</surname><given-names>C.J.</given-names></name>
<name><surname>Est&#x000e8;ve</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Global surveillance of trends in cancer survival 2000&#x02013;14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1023</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33326-3</pub-id><pub-id pub-id-type="pmid">29395269</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00164"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaturvedi</surname><given-names>V.K.</given-names></name>
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>V.K.</given-names></name>
<name><surname>Singh</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy</article-title><source>Curr. Drug Metab.</source><year>2018</year><volume>20</volume><fpage>416</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.2174/1389200219666180918111528</pub-id><pub-id pub-id-type="pmid">30227814</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00164"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Yan</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Gu</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Progress, challenges, and future of nanomedicine</article-title><source>Nano Today</source><year>2020</year><volume>35</volume><fpage>101008</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2020.101008</pub-id></element-citation></ref><ref id="B5-pharmaceutics-17-00164"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olusanya</surname><given-names>T.O.B.</given-names></name>
<name><surname>Haj Ahmad</surname><given-names>R.R.</given-names></name>
<name><surname>Ibegbu</surname><given-names>D.M.</given-names></name>
<name><surname>Smith</surname><given-names>J.R.</given-names></name>
<name><surname>Elkordy</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Liposomal drug delivery systems and anticancer drugs</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>907</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23040907</pub-id><pub-id pub-id-type="pmid">29662019</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00164"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>D.</given-names></name>
<name><surname>Niu</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>A.</given-names></name>
</person-group><article-title>Properties of Poly(lactic-<italic toggle="yes">co</italic>-glycolic acid) and Progress of Poly(lactic-<italic toggle="yes">co</italic>-glycolic acid)-Based Biodegradable Materials in Biomedical Research</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>454</elocation-id><pub-id pub-id-type="doi">10.3390/ph16030454</pub-id><pub-id pub-id-type="pmid">36986553</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00164"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Begines</surname><given-names>B.</given-names></name>
<name><surname>Ortiz</surname><given-names>T.</given-names></name>
<name><surname>P&#x000e9;rez-Aranda</surname><given-names>M.</given-names></name>
<name><surname>Mart&#x000ed;nez</surname><given-names>G.</given-names></name>
<name><surname>Merinero</surname><given-names>M.</given-names></name>
<name><surname>Arg&#x000fc;elles-Arias</surname><given-names>F.</given-names></name>
<name><surname>Alcudia</surname><given-names>A.</given-names></name>
</person-group><article-title>Polymeric nanoparticles for drug delivery: Recent developments and future prospects</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><elocation-id>1403</elocation-id><pub-id pub-id-type="doi">10.3390/nano10071403</pub-id><pub-id pub-id-type="pmid">32707641</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00164"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohanty</surname><given-names>A.</given-names></name>
<name><surname>Uthaman</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>I.-K.</given-names></name>
</person-group><article-title>Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>4377</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25194377</pub-id><pub-id pub-id-type="pmid">32977707</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00164"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mukherjee</surname><given-names>A.</given-names></name>
<name><surname>Waters</surname><given-names>A.K.</given-names></name>
<name><surname>Kalyan</surname><given-names>P.</given-names></name>
<name><surname>Achrol</surname><given-names>A.S.</given-names></name>
<name><surname>Kesari</surname><given-names>S.</given-names></name>
<name><surname>Yenugonda</surname><given-names>V.M.</given-names></name>
</person-group><article-title>Lipid&#x02013;polymer hybrid nanoparticles as a next-generation drug delivery platform: State of the art, emerging technologies, and perspectives</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>14</volume><fpage>1937</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.2147/IJN.S198353</pub-id><pub-id pub-id-type="pmid">30936695</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00164"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krishnamurthy</surname><given-names>S.</given-names></name>
<name><surname>Vaiyapuri</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Chan</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Lipid-coated polymeric nanoparticles for cancer drug delivery</article-title><source>Biomater. Sci.</source><year>2015</year><volume>3</volume><fpage>923</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1039/C4BM00427B</pub-id><pub-id pub-id-type="pmid">26221931</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00164"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berois</surname><given-names>N.</given-names></name>
<name><surname>Pittini</surname><given-names>A.</given-names></name>
<name><surname>Osinaga</surname><given-names>E.</given-names></name>
</person-group><article-title>Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>645</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14030645</pub-id><pub-id pub-id-type="pmid">35158915</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00164"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mereiter</surname><given-names>S.</given-names></name>
<name><surname>Balma&#x000f1;a</surname><given-names>M.</given-names></name>
<name><surname>Campos</surname><given-names>D.</given-names></name>
<name><surname>Gomes</surname><given-names>J.</given-names></name>
<name><surname>Reis</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?</article-title><source>Cancer Cell</source><year>2019</year><volume>36</volume><fpage>6</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.06.006</pub-id><pub-id pub-id-type="pmid">31287993</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00164"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ju</surname><given-names>T.</given-names></name>
<name><surname>Otto</surname><given-names>V.I.</given-names></name>
<name><surname>Cummings</surname><given-names>R.D.</given-names></name>
</person-group><article-title>The Tn antigen-structural simplicity and biological complexity</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2011</year><volume>50</volume><fpage>1770</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1002/anie.201002313</pub-id><pub-id pub-id-type="pmid">21259410</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00164"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ju</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Aryal</surname><given-names>R.P.</given-names></name>
<name><surname>Lehoux</surname><given-names>S.D.</given-names></name>
<name><surname>Ding</surname><given-names>X.</given-names></name>
<name><surname>Kudelka</surname><given-names>M.R.</given-names></name>
<name><surname>Cutler</surname><given-names>C.</given-names></name>
<name><surname>Zeng</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Tn and sialyl-Tn antigens, aberrant <italic toggle="yes">O</italic>-glycomics as human disease markers</article-title><source>Proteom. Clin. Appl.</source><year>2013</year><volume>7</volume><fpage>618</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1002/prca.201300024</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-00164"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osinaga</surname><given-names>E.</given-names></name>
<name><surname>Bay</surname><given-names>S.</given-names></name>
<name><surname>Tello</surname><given-names>D.</given-names></name>
<name><surname>Babino</surname><given-names>A.</given-names></name>
<name><surname>Pritsch</surname><given-names>O.</given-names></name>
<name><surname>Assemat</surname><given-names>K.</given-names></name>
<name><surname>Cantacuzene</surname><given-names>D.</given-names></name>
<name><surname>Nakada</surname><given-names>H.</given-names></name>
<name><surname>Alzari</surname><given-names>P.</given-names></name>
</person-group><article-title>Analysis of the fine specificity of Tn-binding proteins using synthetic glycopeptide epitopes and a biosensor based on surface plasmon resonance spectroscopy</article-title><source>FEBS Lett.</source><year>2000</year><volume>469</volume><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)01248-5</pub-id><pub-id pub-id-type="pmid">10708749</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00164"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hubert</surname><given-names>P.</given-names></name>
<name><surname>Heitzmann</surname><given-names>A.</given-names></name>
<name><surname>Viel</surname><given-names>S.</given-names></name>
<name><surname>Nicolas</surname><given-names>A.</given-names></name>
<name><surname>Sastre-Garau</surname><given-names>X.</given-names></name>
<name><surname>Oppezzo</surname><given-names>P.</given-names></name>
<name><surname>Pritsch</surname><given-names>O.</given-names></name>
<name><surname>Osinaga</surname><given-names>E.</given-names></name>
<name><surname>Amigorena</surname><given-names>S.</given-names></name>
</person-group><article-title>Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>5134</fpage><lpage>5143</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4222</pub-id><pub-id pub-id-type="pmid">21697279</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00164"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sedlik</surname><given-names>C.</given-names></name>
<name><surname>Heitzmann</surname><given-names>A.</given-names></name>
<name><surname>Viel</surname><given-names>S.</given-names></name>
<name><surname>Ait Sarkouh</surname><given-names>R.</given-names></name>
<name><surname>Batisse</surname><given-names>C.</given-names></name>
<name><surname>Schmidt</surname><given-names>F.</given-names></name>
<name><surname>De La Rochere</surname><given-names>P.</given-names></name>
<name><surname>Amzallag</surname><given-names>N.</given-names></name>
<name><surname>Osinaga</surname><given-names>E.</given-names></name>
<name><surname>Oppezzo</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen</article-title><source>OncoImmunology</source><year>2016</year><volume>5</volume><fpage>e1171434</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2016.1171434</pub-id><pub-id pub-id-type="pmid">27622021</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00164"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castro</surname><given-names>A.</given-names></name>
<name><surname>Berois</surname><given-names>N.</given-names></name>
<name><surname>Malanga</surname><given-names>A.</given-names></name>
<name><surname>Ortega</surname><given-names>C.</given-names></name>
<name><surname>Oppezzo</surname><given-names>P.</given-names></name>
<name><surname>Pristch</surname><given-names>O.</given-names></name>
<name><surname>Mombr&#x000fa;</surname><given-names>A.W.</given-names></name>
<name><surname>Osinaga</surname><given-names>E.</given-names></name>
<name><surname>Pardo</surname><given-names>H.</given-names></name>
</person-group><article-title>Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse/human chimeric antibody as a promising targeting strategy of lung tumors</article-title><source>Int. J. Biol. Macromol.</source><year>2021</year><volume>182</volume><fpage>806</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.04.054</pub-id><pub-id pub-id-type="pmid">33857513</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00164"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bose</surname><given-names>R.J.</given-names></name>
<name><surname>Lee</surname><given-names>S.-H.</given-names></name>
<name><surname>Park</surname><given-names>H.</given-names></name>
</person-group><article-title>Lipid polymer hybrid nanospheres encapsulating antiproliferative agents for stent applications</article-title><source>J. Ind. Eng. Chem.</source><year>2016</year><volume>36</volume><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.jiec.2016.02.015</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-00164"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Xing</surname><given-names>H.</given-names></name>
<name><surname>Song</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Qiu</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Ren</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
</person-group><article-title>Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin</article-title><source>J. Pharm. Sci.</source><year>2016</year><volume>105</volume><fpage>2949</fpage><lpage>2958</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2016.03.038</pub-id><pub-id pub-id-type="pmid">27209461</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00164"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klippstein</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>J.T.-W.</given-names></name>
<name><surname>El-Gogary</surname><given-names>R.I.</given-names></name>
<name><surname>Bai</surname><given-names>J.</given-names></name>
<name><surname>Mustafa</surname><given-names>F.</given-names></name>
<name><surname>Rubio</surname><given-names>N.</given-names></name>
<name><surname>Bansal</surname><given-names>S.</given-names></name>
<name><surname>Al-Jamal</surname><given-names>W.T.</given-names></name>
<name><surname>Al-Jamal</surname><given-names>K.T.</given-names></name>
</person-group><article-title>Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo</article-title><source>Small</source><year>2015</year><volume>11</volume><fpage>4704</fpage><lpage>4722</lpage><pub-id pub-id-type="doi">10.1002/smll.201403799</pub-id><pub-id pub-id-type="pmid">26140363</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00164"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sayour</surname><given-names>E.J.</given-names></name>
<name><surname>Mendez-Gomez</surname><given-names>H.R.</given-names></name>
<name><surname>Mitchell</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Cancer vaccine immunotherapy with RNA-loaded liposomes</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>2890</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19102890</pub-id><pub-id pub-id-type="pmid">30249040</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00164"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>R.W.</given-names></name>
<name><surname>Benz</surname><given-names>F.</given-names></name>
<name><surname>Sigle</surname><given-names>D.O.</given-names></name>
<name><surname>Bowman</surname><given-names>R.W.</given-names></name>
<name><surname>Bao</surname><given-names>P.</given-names></name>
<name><surname>Roth</surname><given-names>J.S.</given-names></name>
<name><surname>Heath</surname><given-names>G.R.</given-names></name>
<name><surname>Evans</surname><given-names>S.D.</given-names></name>
<name><surname>Baumberg</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Watching individual molecules flex within lipid membranes using SERS</article-title><source>Sci. Rep.</source><year>2014</year><volume>4</volume><elocation-id>5940</elocation-id><pub-id pub-id-type="doi">10.1038/srep05940</pub-id><pub-id pub-id-type="pmid">25113088</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00164"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salerno</surname><given-names>M.</given-names></name>
<name><surname>Shayganpour</surname><given-names>A.</given-names></name>
<name><surname>Salis</surname><given-names>B.</given-names></name>
<name><surname>Dante</surname><given-names>S.</given-names></name>
</person-group><article-title>Surface-enhanced Raman scattering of self-assembled thiol monolayers and supported lipid membranes on thin anodic porous alumina</article-title><source>Beilstein J. Nanotechnol.</source><year>2017</year><volume>8</volume><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.3762/bjnano.8.8</pub-id><pub-id pub-id-type="pmid">28144566</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00164"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pigorsch</surname><given-names>E.</given-names></name>
</person-group><article-title>Spectroscopic characterisation of cationic quaternary ammonium starches</article-title><source>Starch/St&#x000e4;rke</source><year>2009</year><volume>61</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1002/star.200800090</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-00164"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vanden-Hehir</surname><given-names>S.</given-names></name>
<name><surname>Tipping</surname><given-names>W.J.</given-names></name>
<name><surname>Lee</surname><given-names>M.</given-names></name>
<name><surname>Brunton</surname><given-names>V.G.</given-names></name>
<name><surname>Williams</surname><given-names>A.</given-names></name>
<name><surname>Hulme</surname><given-names>A.N.</given-names></name>
</person-group><article-title>Raman imaging of nanocarriers for drug delivery</article-title><source>Nanomaterials</source><year>2019</year><volume>9</volume><elocation-id>341</elocation-id><pub-id pub-id-type="doi">10.3390/nano9030341</pub-id><pub-id pub-id-type="pmid">30832394</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00164"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Augustine</surname><given-names>R.</given-names></name>
<name><surname>Hasan</surname><given-names>A.</given-names></name>
<name><surname>Primavera</surname><given-names>R.</given-names></name>
<name><surname>Wilson</surname><given-names>R.J.</given-names></name>
<name><surname>Thakor</surname><given-names>A.S.</given-names></name>
<name><surname>Kevadiya</surname><given-names>B.D.</given-names></name>
</person-group><article-title>Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components</article-title><source>Mater. Today Commun.</source><year>2020</year><volume>25</volume><fpage>101692</fpage><pub-id pub-id-type="doi">10.1016/j.mtcomm.2020.101692</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-00164"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabourian</surname><given-names>P.</given-names></name>
<name><surname>Yazdani</surname><given-names>G.</given-names></name>
<name><surname>Ashraf</surname><given-names>S.S.</given-names></name>
<name><surname>Frounchi</surname><given-names>M.</given-names></name>
<name><surname>Mashayekhan</surname><given-names>S.</given-names></name>
<name><surname>Kiani</surname><given-names>S.</given-names></name>
<name><surname>Kakkar</surname><given-names>A.</given-names></name>
</person-group><article-title>Effect of physico-chemical properties of nanoparticles on their intracellular uptake</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>8019</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21218019</pub-id><pub-id pub-id-type="pmid">33126533</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00164"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>S.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Peng</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery</article-title><source>Nanoscale</source><year>2021</year><volume>13</volume><fpage>10748</fpage><lpage>10764</lpage><pub-id pub-id-type="doi">10.1039/D1NR02065J</pub-id><pub-id pub-id-type="pmid">34132312</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00164"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>S.-J.</given-names></name>
<name><surname>Wang</surname><given-names>T.-H.</given-names></name>
<name><surname>Chou</surname><given-names>Y.-H.</given-names></name>
<name><surname>Wang</surname><given-names>H.-M.D.</given-names></name>
<name><surname>Hsu</surname><given-names>T.-C.</given-names></name>
<name><surname>Yow</surname><given-names>J.-L.</given-names></name>
<name><surname>Tzang</surname><given-names>B.-S.</given-names></name>
<name><surname>Chiang</surname><given-names>W.-H.</given-names></name>
</person-group><article-title>Hybrid PEGylated chitosan/PLGA nanoparticles designed as pH-responsive vehicles to promote intracellular drug delivery and cancer chemotherapy</article-title><source>Int. J. Biol. Macromol.</source><year>2022</year><volume>210</volume><fpage>565</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2022.04.209</pub-id><pub-id pub-id-type="pmid">35513093</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00164"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>S.</given-names></name>
<name><surname>Dagn&#x000e6;s-Hansen</surname><given-names>F.</given-names></name>
<name><surname>Jakobsen</surname><given-names>M.</given-names></name>
<name><surname>Kjems</surname><given-names>J.</given-names></name>
</person-group><article-title>Impact of PEG Chain Length on the Physical Properties and Bioactivity of PEGylated Chitosan/siRNA Nanoparticles in Vitro and in Vivo</article-title><source>ACS Appl. Mater. Interfaces</source><year>2017</year><volume>9</volume><fpage>12203</fpage><lpage>12216</lpage><pub-id pub-id-type="doi">10.1021/acsami.6b16556</pub-id><pub-id pub-id-type="pmid">28332829</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00164"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>P.</given-names></name>
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Verma</surname><given-names>A.K.</given-names></name>
<name><surname>Kant</surname><given-names>S.</given-names></name>
<name><surname>Pandey</surname><given-names>A.K.</given-names></name>
<name><surname>Khare</surname><given-names>P.</given-names></name>
<name><surname>Prakash</surname><given-names>V.</given-names></name>
</person-group><article-title>The Anti-Tumor and Immunomodulatory Effects of PLGA-Based Docetaxel Nanoparticles in Lung Cancer: The Potential Involvement of Necroptotic Cell Death through Reactive Oxygen Species and Calcium Build-Up</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1801</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10111801</pub-id><pub-id pub-id-type="pmid">36366309</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00164"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Chan</surname><given-names>J.M.</given-names></name>
<name><surname>Gu</surname><given-names>F.X.</given-names></name>
<name><surname>Rhee</surname><given-names>J.-W.</given-names></name>
<name><surname>Wang</surname><given-names>A.Z.</given-names></name>
<name><surname>Radovic-Moreno</surname><given-names>A.F.</given-names></name>
<name><surname>Alexis</surname><given-names>F.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>Farokhzad</surname><given-names>O.C.</given-names></name>
</person-group><article-title>Self-assembled lipid&#x02212;polymer hybrid nanoparticles: A robust drug delivery platform</article-title><source>ACS Nano</source><year>2008</year><volume>2</volume><fpage>1696</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1021/nn800275r</pub-id><pub-id pub-id-type="pmid">19206374</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00164"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Ji</surname><given-names>H.</given-names></name>
<name><surname>Peng</surname><given-names>R.</given-names></name>
<name><surname>Jin</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
</person-group><article-title>Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>6885</fpage><lpage>6900</lpage><pub-id pub-id-type="doi">10.7150/thno.36510</pub-id><pub-id pub-id-type="pmid">31660075</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00164"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torrecilla</surname><given-names>D.</given-names></name>
<name><surname>Lozano</surname><given-names>M.V.</given-names></name>
<name><surname>Lallana</surname><given-names>E.</given-names></name>
<name><surname>Neissa</surname><given-names>J.I.</given-names></name>
<name><surname>Novoa-Carballal</surname><given-names>R.</given-names></name>
<name><surname>Vidal</surname><given-names>A.</given-names></name>
<name><surname>Fernandez-Megia</surname><given-names>E.</given-names></name>
<name><surname>Torres</surname><given-names>D.</given-names></name>
<name><surname>Riguera</surname><given-names>R.</given-names></name>
<name><surname>Alonso</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Anti-tumor efficacy of chitosan-g-poly(ethylene glycol) nanocapsules containing docetaxel: Anti-TMEFF-2 functionalized nanocapsules vs. non-functionalized nanocapsules</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2013</year><volume>83</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2012.10.017</pub-id><pub-id pub-id-type="pmid">23262164</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00164"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sonin</surname><given-names>D.</given-names></name>
<name><surname>Pochkaeva</surname><given-names>E.</given-names></name>
<name><surname>Zhuravskii</surname><given-names>S.</given-names></name>
<name><surname>Postnov</surname><given-names>V.</given-names></name>
<name><surname>Korolev</surname><given-names>D.</given-names></name>
<name><surname>Vasina</surname><given-names>L.</given-names></name>
<name><surname>Kostina</surname><given-names>D.</given-names></name>
<name><surname>Mukhametdinova</surname><given-names>D.</given-names></name>
<name><surname>Zelinskaya</surname><given-names>I.</given-names></name>
<name><surname>Skorik</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Biological safety and biodistribution of chitosan nanoparticles</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><elocation-id>810</elocation-id><pub-id pub-id-type="doi">10.3390/nano10040810</pub-id><pub-id pub-id-type="pmid">32340313</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00164"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Da Silva</surname><given-names>C.</given-names></name>
<name><surname>Rueda</surname><given-names>F.</given-names></name>
<name><surname>L&#x000f6;wik</surname><given-names>C.</given-names></name>
<name><surname>Ossendorp</surname><given-names>F.</given-names></name>
<name><surname>Cruz</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Combinatorial prospects of nano-targeted chemoimmunotherapy</article-title><source>Biomaterials</source><year>2016</year><volume>83</volume><fpage>308</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.01.006</pub-id><pub-id pub-id-type="pmid">26796043</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00164"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>D.</given-names></name>
<name><surname>Shigdar</surname><given-names>S.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name>
<name><surname>Duan</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
</person-group><article-title>Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells</article-title><source>Int. J. Nanomed.</source><year>2014</year><volume>9</volume><fpage>1083</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.2147/IJN.S59779</pub-id></element-citation></ref><ref id="B39-pharmaceutics-17-00164"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bao</surname><given-names>Y.</given-names></name>
<name><surname>Deng</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>S.</given-names></name>
</person-group><article-title>Engineering docetaxel-loaded micelles for non-small cell lung cancer: A comparative study of microfluidic and bulk nanoparticle preparation</article-title><source>RSC Adv.</source><year>2018</year><volume>8</volume><fpage>31950</fpage><lpage>31966</lpage><pub-id pub-id-type="doi">10.1039/C8RA04512G</pub-id><pub-id pub-id-type="pmid">35547502</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00164"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Lee</surname><given-names>R.J.</given-names></name>
<name><surname>Sun</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Teng</surname><given-names>L.</given-names></name>
</person-group><article-title>Trastuzumab-Coated Nanoparticles Loaded with Docetaxel for Breast Cancer Therapy</article-title><source>Dose-Response</source><year>2019</year><volume>17</volume><fpage>1559325819872583</fpage><pub-id pub-id-type="doi">10.1177/1559325819872583</pub-id><pub-id pub-id-type="pmid">31523204</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00164"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panaampon</surname><given-names>J.</given-names></name>
<name><surname>Sasamoto</surname><given-names>K.</given-names></name>
<name><surname>Kariya</surname><given-names>R.</given-names></name>
<name><surname>Okada</surname><given-names>S.</given-names></name>
</person-group><article-title>Establishment of Nude Mice Lacking NK Cells and Their Application for Human Tumor Xenografts</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2021</year><volume>22</volume><fpage>1069</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.31557/APJCP.2021.22.4.1069</pub-id><pub-id pub-id-type="pmid">33906298</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00164-f001"><label>Figure 1</label><caption><p>Raman spectrum of DSPE-PEG (a), DSPE-PEG-Biotin (b), PLGA (c), LPHNp (d), DOTAP-Cl (e), and crodamol (f).</p></caption><graphic xlink:href="pharmaceutics-17-00164-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00164-f002"><label>Figure 2</label><caption><p>Morphological analysis of LPHNp-DCX-Chi-Tn using HR-TEM (<bold>A</bold>,<bold>B</bold>) and AFM (<bold>C</bold>,<bold>D</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00164-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00164-f003"><label>Figure 3</label><caption><p>In vitro drug release of DCX from LPHNp-DCX-Chi-Tn mAb in buffer at pH 7.4 and 5 at 37 &#x000b0;C (<bold>A</bold>). Size distribution of LPHNp during 27 days of storage at 4 &#x000b0;C (<bold>B</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00164-g003" position="float"/></fig><fig position="float" id="pharmaceutics-17-00164-f004"><label>Figure 4</label><caption><p>Uptake study of fluorescent LPHNp in A549 cancer cells. (<bold>A</bold>&#x02013;<bold>F</bold>) Images obtained by CLSM of untreated cells (<bold>A</bold>,<bold>D</bold>), LPHN-coumarin (<bold>B</bold>,<bold>E</bold>), and LPHN-coumarin-ChiTn mAb (<bold>C</bold>,<bold>F</bold>) incubated at 4 &#x000b0;C (<bold>A</bold>&#x02013;<bold>C</bold>) or 37 &#x000b0;C (<bold>D</bold>&#x02013;<bold>F</bold>). (<bold>G</bold>) Percentage of 6-coumarin positive cells evaluated by flow cytometry. Numbers 1, 2, and 3 represent untreated cells, LPHN-coumarin-treated cells, and LPHN-coumarin-ChiTn mAb-treated cells, respectively. (<bold>H</bold>) Mean fluorescence intensity (MFI) of untreated cells (1), LPHN-coumarin-treated cells (2), and LPHN-coumarin-ChiTn mAb-treated cells determined by flow cytometry. Significant differences between groups are indicated by asterisks: * represents <italic toggle="yes">p</italic> &#x0003c; 0.05, ** represents <italic toggle="yes">p</italic> &#x0003c; 0.01, and *** represents <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="pharmaceutics-17-00164-g004" position="float"/></fig><fig position="float" id="pharmaceutics-17-00164-f005"><label>Figure 5</label><caption><p>Cell viability was assessed in the A549 cell line using the CCK-8 assay for free DCX and DCX-loaded LPHNp formulations at varying concentrations over 24, 48, and 72 h. Significant differences are denoted by asterisks (*, <italic toggle="yes">p</italic> &#x0003c; 0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01; ***, <italic toggle="yes">p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="pharmaceutics-17-00164-g005" position="float"/></fig><fig position="float" id="pharmaceutics-17-00164-f006"><label>Figure 6</label><caption><p>Anti-tumor effect in vivo. <italic toggle="yes">Nude</italic> mice were inoculated with the A549 lung tumor cell line. When the tumors reached approximately 100 mm<sup>3</sup>, the animals were treated intraperitoneally with different treatments: PBS, free DCX (Taxotere), LPHNp-DCX-Chi-Tn, LPHNp-DCX, and 6, LPHNp-Chi-Tn, each formulation at 10 mg DCX/kg. The treatment was administered three times every four days. The black arrows indicate the days on which treatment was given. (<bold>A</bold>) Inhibition of lung tumor xenograft growth in the <italic toggle="yes">nude</italic> mice by the nanoparticle formulations. Data are presented as mean &#x000b1; SD. (<bold>B</bold>) Kaplan&#x02013;Meier survival curve of the treated mice. (<bold>C</bold>) Body weight was measured at the indicated times. Data are presented as mean &#x000b1; SD. Significant differences are denoted by asterisks (*, <italic toggle="yes">p</italic> &#x0003c; 0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01; ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001).</p></caption><graphic xlink:href="pharmaceutics-17-00164-g006" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00164-t001"><object-id pub-id-type="pii">pharmaceutics-17-00164-t001_Table 1</object-id><label>Table 1</label><caption><p>Physicochemical properties of the nanosystems obtained (mean &#x000b1; S.D.; n = 3).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Size &#x000b1; SD (nm)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IP &#x000b1; SD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Z Potential &#x000b1; SD (mV)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EE &#x000b1; SD (%)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">LPHNp</td><td align="center" valign="middle" rowspan="1" colspan="1">201.9 &#x000b1; 2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1 &#x000b1; 0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">32.1 &#x000b1; 1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LPHNp-Chi-Tn mAb </td><td align="center" valign="middle" rowspan="1" colspan="1">205.5 &#x000b1; 1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2 &#x000b1; 0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">36.6 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LPHNp-DCX</td><td align="center" valign="middle" rowspan="1" colspan="1">222.5 &#x000b1; 1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1 &#x000b1; 0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">36.0 &#x000b1; 0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">99.92 &#x000b1; 0.01</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPHNp-DCX-Chi-Tn mAb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">232.3 &#x000b1; 2.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2 &#x000b1; 0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.6 &#x000b1; 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.92 &#x000b1; 0.01</td></tr></tbody></table></table-wrap></floats-group></article>